Unknown

Dataset Information

0

Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.

ABSTRACT: Herein, novel hepatitis C virus NS3/4A protease inhibitors based on a P2 pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl sulfonamide functionality in P1 are presented. The P1' 4-(trifluoromethyl)phenyl side chain was shown to be particularly beneficial in terms of inhibitory potency. Several inhibitors with K i-values in the nanomolar range were developed and included identification of promising P3-truncated inhibitors spanning from P2-P1'. Of several different P2 capping groups that were evaluated, a preference for the sterically congested Boc group was revealed. The inhibitors were found to retain inhibitory potencies for A156T, D168V, and R155K variants of the protease. Furthermore, in vitro pharmacokinetic profiling showed several beneficial effects on metabolic stability as well as on apparent intestinal permeability from both P3 truncation and the use of the P1' 4-(trifluoromethyl)phenyl side chain.

SUBMITTER: Lampa AK 

PROVIDER: S-EPMC4027635 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.

Lampa Anna K AK   Bergman Sara M SM   Gustafsson Sofia S SS   Alogheli Hiba H   Akerblom Eva B EB   Lindeberg Gunnar G GG   Svensson Richard M RM   Artursson Per P   Danielson U Helena UH   Karlén Anders A   Sandström Anja A  

ACS medicinal chemistry letters 20130802 3

Herein, novel hepatitis C virus NS3/4A protease inhibitors based on a P2 pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl sulfonamide functionality in P1 are presented. The P1' 4-(trifluoromethyl)phenyl side chain was shown to be particularly beneficial in terms of inhibitory potency. Several inhibitors with K i-values in the nanomolar range were developed and included identification of promising P3-truncated inhibitors spanning from P2-P1'. Of several differe  ...[more]

Similar Datasets

Unknown Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.
| S-EPMC5748155 | biostudies-literature
Unknown Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors.
| S-EPMC7717897 | biostudies-literature
Unknown Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors.
| S-EPMC4027630 | biostudies-literature
Unknown Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.
| S-EPMC9228641 | biostudies-literature
Unknown The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
| S-EPMC3406087 | biostudies-literature
Unknown Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase.
| S-EPMC2573085 | biostudies-other
Unknown Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant.
| S-EPMC6796237 | biostudies-literature
Unknown Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel.
| S-EPMC3185733 | biostudies-literature
Unknown Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
| S-EPMC3288278 | biostudies-literature
Unknown High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants.
| S-EPMC3493962 | biostudies-literature